Why Spinogenix’s tazbentetol data could reshape glaucoma and diabetic retinopathy research
Retinal disease care still targets drivers. Spinogenix is testing whether synaptic regeneration can protect vision when damage continues.
GenSight Biologics begins LHON treatment under France compassionate access as REVISE Phase II moves forward
GenSight Biologics begins treating ND4-LHON patients under France’s AAC compassionate access program. Analyse what REVISE and AAC mean for the regulatory pathway.